Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
| 9.01 | |
| 9.04 | |
| - | |
| 9.22 | |
| 8.86 | |
| 3.26-10.03 | |
| 575 M | |
| 64 677 K | |
| 1 000 K | |
| -0.3 | |
| -0.382 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the b...
Some of the market’s favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom. On May 26, Viking Therapeutics (NASDAQ:VKTX) was trading around $20.25. Toda...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
